SCHEMBL13067222

SCHEMBL13067222

Cc1cc(O)nc(SCc2ccccc2F)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGAM O43451 1/20 0.51
GAA P10253 1/20 0.51
SI P14410 1/20 0.51
MGAM2 Q2M2H8 1/20 0.51
LMNA P02545 3/20 0.51
TDP1 Q9NUW8 2/20 0.51
L3MBTL1 Q9Y468 2/20 0.51
PKM P14618 2/20 0.51
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
HTT P42858 1/20 0.47
METAP2 P50579 2/20 0.45
CTSB P07858 1/20 0.44
TOP2A P11388 1/20 0.44
MAPT P10636 4/20 0.43
TP53 P04637 1/20 0.43
HPGD P15428 2/20 0.43
TSHR P16473 1/20 0.43
ALPL P05186 1/20 0.43
MPO P05164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16920967 0.85 SMN1; SMN2 (0.52) GAALMNATDP1L3MBTL1MEN1
SCHEMBL862015 0.84 MEN1 (0.66) LMNAPKMMEN1KMT2AHTT
SCHEMBL5314567 0.83 HPGD (0.60) MGAMGAASIMGAM2LMNA
SCHEMBL6354578 0.83 MGAM (0.51) MGAMGAASIMGAM2LMNA
SCHEMBL844933 0.82 HTT (0.43) GAALMNATDP1L3MBTL1PKM
SCHEMBL13066756 0.82 HTT (0.43) MGAMGAASIMGAM2LMNA
SCHEMBL844732 0.82 HTT (0.43) MGAMGAASIMGAM2LMNA
SCHEMBL13066759 0.81 MEN1 (0.48) GAALMNATDP1PKMMEN1
SCHEMBL1520968 0.79 SMN1; SMN2 (0.57) GAALMNATDP1L3MBTL1PKM
SCHEMBL843922 0.79 ALDH1A1 (0.43) GAALMNATDP1L3MBTL1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2432776-B1 METHYL SULFANYL PYRIMIDINES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS UNIV LAVAL (CA) 2019-09-11 EP disclosed
US-9315521-B2 Pyrimidines as novel therapeutic agents UNIVERSITé LAVAL (CA) 2016-04-19 US disclosed
US-9315521-B2 Pyrimidines as novel therapeutic agents UNIVERSITé LAVAL (CA) 2016-04-19 US disclosed
US-20150225423-A1 PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS UNIVERSITé LAVAL (CA) 2015-08-13 US disclosed
US-20150225423-A1 PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS UNIVERSITé LAVAL (CA) 2015-08-13 US disclosed
US-9040538-B2 Pyrimidines as novel therapeutic agents UNIVERSITE LAVAL (CA) 2015-05-26 US disclosed
US-20100298336-A1 PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS UNIVERSITE LAVAL (CA) 2010-11-25 US disclosed
WO-2010132999-A1 METHYL SULFANYL PYRMIDMES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS CHLORION PHARMA, INC. (CA) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298336-A1 PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS TYMS, P2RX2, TYMP MGAM 4700/4885GAA 1107/4885SI 1041/4885
US-20150225423-A1 PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS TYMS, P2RX2, TYMP MGAM 4700/4885GAA 1107/4885SI 1041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.